@MathieuSpaas profile picture
Mathieu Spaas @MathieuSpaas
Joined September 2018
  • Tweets 15
  • Following 38
  • Followers 39
3 Photos and videos
Pinned Tweet
Mathieu Spaas@MathieuSpaas
7 Jul 2023
📣We just published final results of our CHEERS trial @JAMAOnc investigating the combination of subtotal subablative SBRT ☢️ with anti-PD-(L)1 monotherapy 💉 in pts with advanced solid tumors ja.ma/3pBquxM

7
35
65
17,944
Absolutely, some more insight into overall disease burden is provided in the online supplements 🔎
Nicholas Zaorsky, MD MS@NicholasZaorsky
7 Jul 2023
Replying to @MathieuSpaas @JAMAOnc
Also, consider disease volume and velocity. If these are high, any therapy may have limited benefit. pubmed.ncbi.nlm.nih.gov/3359… If 7/45 pts had progression pre treatment, >2/3 were >1st line systemic tx, 50% had progression at 3 mos follow-up, it is likely a high risk cohort.
3
2
1,126
📣We just published final results of our CHEERS trial @JAMAOnc investigating the combination of subtotal subablative SBRT ☢️ with anti-PD-(L)1 monotherapy 💉 in pts with advanced solid tumors ja.ma/3pBquxM

7
35
65
17,944
more replies
✅Conclusion: while safe, adding subablative multisite SBRT to anti-PD-(L)1 monotherapy did not result in a clinically meaningful benefit 🙏 Thank you to pts, families, trial staff and investigators for participating in this @komop_tgkanker and @VarianMedSys sponsored trial!
1
5
9
1,045
@piet_ost @NoraSundahl @RotteySylvie @Kruse_Vibeke @daandm @BrochezLieve @willekedanckae @Van_den_Begin @GestelDirk @EHulstaert @Sj0mpie
1
3
435
This phase 2 RCT recruited n=99 with advanced melanoma, RCC, UC, HNSCC and NSCLC across 5 Belgian 🇧🇪 hospitals between 2018-2020 ➡️ Randomized 1:1 between 💉anti-PD-(L)1 alone or in combination with ☢️ SBRT 3x8Gy of up to 3 tumor lesions
1
1
1
77
👥 >2/3 polyM pts and >1st line systemic Tx 😷 7/45 pts did not complete SBRT due to early PD or intercurrent illness ☢️ SBRT treated lesions were mostly 🫁 mets and lymph nodes
1
2
78
Mathieu Spaas retweeted
Piet Ost@piet_ost
20 Nov 2021
Words of wisdom on the NIVES trial: SBRT nivo in mRCC. Our take on what is next and abandon the quest for the "abscopal" effect. @MathieuSpaas @NoraSundahl @_ShankarSiva @rweichselbaum bit.ly/3oOQXDq

1
15
38
Mathieu Spaas retweeted
Melvin LK CHUA | FRCR, PhD, FASCO
@DrMLChua
14 Jun 2020
Really pleased to bring this to fruition. Collaboration between multiple partners to shed insights on combination immunotherapy and radiotherapy, so as to guide best combination therapies! ⁦#RTimmuno #checkpoint blockade #precisionRT ⁦@ASTRO_org⁩ redjournal.org/article/S0360…

4
9
60
Mathieu Spaas retweeted
The Lancet Oncology@TheLancetOncol
3 Jan 2020
Review: Characterisation & classification of #oligometastatic disease: a @ESTRO_RT and @EORTC consensus recommendation thelancet.com/journals/lanon…
1
68
89
Mathieu Spaas retweeted
Robbe Van den Begin@Van_den_Begin
8 Aug 2019
Great news. Let's include as many as possible in the CHEERS trial when starting anti PD(L)-1. Maybe we can further improve the outcome! @JulesBordet #OncoAlert
Philippe Aftimos, MD @aftimosp
8 Aug 2019
#OncoAlert #ImmunoOnc Nivolumab treatment was associated with long-term survival in a subset of heavily pretreated patients with advanced melanoma, RCC, or NSCLC ja.ma/2TeMn10
3
5
Load more